SG Americas Securities LLC Has $159,000 Holdings in Glaukos Co. (NYSE:GKOS)

SG Americas Securities LLC lowered its position in shares of Glaukos Co. (NYSE:GKOS) by 96.9% during the fourth quarter, Holdings Channel reports. The fund owned 2,005 shares of the medical instruments supplier’s stock after selling 63,577 shares during the quarter. SG Americas Securities LLC’s holdings in Glaukos were worth $159,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Tower Research Capital LLC TRC increased its stake in Glaukos by 257.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier’s stock valued at $62,000 after buying an additional 892 shares during the period. Captrust Financial Advisors increased its stake in Glaukos by 17.1% in the 2nd quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 254 shares during the period. CWM LLC increased its stake in Glaukos by 309.5% in the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,046 shares during the period. State of Wyoming grew its position in Glaukos by 28.0% in the second quarter. State of Wyoming now owns 1,565 shares of the medical instruments supplier’s stock worth $111,000 after acquiring an additional 342 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Glaukos by 17.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock worth $137,000 after acquiring an additional 270 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the subject of several recent research reports. Citigroup boosted their target price on shares of Glaukos from $107.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. JPMorgan Chase & Co. raised shares of Glaukos from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $66.00 to $91.00 in a research report on Thursday, December 21st. Needham & Company LLC boosted their target price on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Mizuho boosted their target price on shares of Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Truist Financial reissued a “buy” rating and issued a $110.00 target price on shares of Glaukos in a research report on Monday, April 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.80.

Glaukos Price Performance

Shares of Glaukos stock opened at $96.81 on Tuesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. Glaukos Co. has a fifty-two week low of $45.38 and a fifty-two week high of $102.33. The firm has a fifty day moving average price of $91.77 and a two-hundred day moving average price of $80.18. The company has a market cap of $4.79 billion, a PE ratio of -34.82 and a beta of 1.08.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The company had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. During the same period last year, the company earned ($0.53) earnings per share. Glaukos’s revenue for the quarter was up 15.7% on a year-over-year basis. Analysts expect that Glaukos Co. will post -2.18 EPS for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 583 shares of the stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $90.54, for a total value of $52,784.82. Following the completion of the sale, the chief financial officer now directly owns 54,618 shares of the company’s stock, valued at approximately $4,945,113.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Mark J. Foley sold 4,560 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $92.87, for a total value of $423,487.20. Following the completion of the transaction, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Alex R. Thurman sold 583 shares of the stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $90.54, for a total transaction of $52,784.82. Following the completion of the transaction, the chief financial officer now owns 54,618 shares of the company’s stock, valued at approximately $4,945,113.72. The disclosure for this sale can be found here. Insiders sold a total of 243,464 shares of company stock valued at $22,959,418 in the last ninety days. Company insiders own 7.80% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.